Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).

Paolo Antonio Ascierto; Lev V. Demidov; Claus Garbe; Paul Lorigan; Helen Gogas; Christoph Hoeller; John B. A. G. Haanen; Enrique Espinosa; Tormod Kyrre Guren; Eva Muñoz-Couselo; Andree Rorive; Piotr Rutkowski; Reinhard Dummer; Ana Carneiro; Geke Hospers; Frank Hermann; Joel Jiang; Dirk Schadendorf; Paul D. Nathan

doi:10.1200/jco.2016.34.15_suppl.9526

Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).

Paolo Antonio Ascierto, Lev V. Demidov, Claus Garbe, Paul Lorigan, Helen Gogas, Christoph Hoeller, John B. A. G. Haanen, Enrique Espinosa, Tormod Kyrre Guren, Eva Muñoz-Couselo, Andree Rorive, Piotr Rutkowski, Reinhard Dummer, Ana Carneiro, Geke Hospers, Frank Hermann, Joel Jiang, Dirk Schadendorf, Paul D. Nathan

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	9526-9526
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	34
Issue number	15_suppl
DOIs	https://doi.org/10.1200/jco.2016.34.15_suppl.9526
Publication status	Published - 6 Sept 2018

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/jco.2016.34.15_suppl.9526

Cite this

Ascierto, P. A., Demidov, L. V., Garbe, C., Lorigan, P., Gogas, H., Hoeller, C., Haanen, J. B. A. G., Espinosa, E., Guren, T. K., Muñoz-Couselo, E., Rorive, A., Rutkowski, P., Dummer, R., Carneiro, A., Hospers, G., Hermann, F., Jiang, J., Schadendorf, D., & Nathan, P. D. (2018). Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172). Journal of Clinical Oncology, 34(15_suppl), 9526-9526. https://doi.org/10.1200/jco.2016.34.15_suppl.9526

@article{02071faefb794cd38f8708bc04469d46,

title = "Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).",

author = "Ascierto, {Paolo Antonio} and Demidov, {Lev V.} and Claus Garbe and Paul Lorigan and Helen Gogas and Christoph Hoeller and Haanen, {John B. A. G.} and Enrique Espinosa and Guren, {Tormod Kyrre} and Eva Mu{\~n}oz-Couselo and Andree Rorive and Piotr Rutkowski and Reinhard Dummer and Ana Carneiro and Geke Hospers and Frank Hermann and Joel Jiang and Dirk Schadendorf and Nathan, {Paul D.}",

year = "2018",

month = sep,

day = "6",

doi = "10.1200/jco.2016.34.15_suppl.9526",

language = "English",

volume = "34",

pages = "9526--9526",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins",

number = "15_suppl",

}

Ascierto, PA, Demidov, LV, Garbe, C, Lorigan, P, Gogas, H, Hoeller, C, Haanen, JBAG, Espinosa, E, Guren, TK, Muñoz-Couselo, E, Rorive, A, Rutkowski, P, Dummer, R, Carneiro, A, Hospers, G, Hermann, F, Jiang, J, Schadendorf, D & Nathan, PD 2018, 'Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).', Journal of Clinical Oncology, vol. 34, no. 15_suppl, pp. 9526-9526. https://doi.org/10.1200/jco.2016.34.15_suppl.9526

Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172). / Ascierto, Paolo Antonio; Demidov, Lev V.; Garbe, Claus et al.
In: Journal of Clinical Oncology, Vol. 34, No. 15_suppl, 06.09.2018, p. 9526-9526.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): A single-arm, open-label, multicenter, phase II study (CheckMate 172).

AU - Ascierto, Paolo Antonio

AU - Demidov, Lev V.

AU - Garbe, Claus

AU - Lorigan, Paul

AU - Gogas, Helen

AU - Hoeller, Christoph

AU - Haanen, John B. A. G.

AU - Espinosa, Enrique

AU - Guren, Tormod Kyrre

AU - Muñoz-Couselo, Eva

AU - Rorive, Andree

AU - Rutkowski, Piotr

AU - Dummer, Reinhard

AU - Carneiro, Ana

AU - Hospers, Geke

AU - Hermann, Frank

AU - Jiang, Joel

AU - Schadendorf, Dirk

AU - Nathan, Paul D.

PY - 2018/9/6

Y1 - 2018/9/6

U2 - 10.1200/jco.2016.34.15_suppl.9526

DO - 10.1200/jco.2016.34.15_suppl.9526

M3 - Meeting Abstract

SN - 0732-183X

VL - 34

SP - 9526

EP - 9526

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 15_suppl

ER -